Novo Ventures Leads US$ 55M Series B Investment in NodThera

Novo Ventures, part of Novo Holdings, today announced that it has led the $55 million (£44 million) Series B financing in NodThera, a UK and US based clinical stage biotechnology company developing a new class of medicines to treat diseases driven by chronic inflammation.

Nanna Lüneborg, Partner at Novo Ventures, will join the NodThera board.

Read more….

 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH